B-UVB phototherapy versus Excimerlaser after minigrafting in vitiligo patients - NB-UVB versus Excimerlaser after minigrafting

Academisch Medisch Centrum0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•i. Consecutive patients, diagnosed with stable vitiligo vulgaris* with symmetrical vitiligo patches
•*Vitiligo vulgaris: a few to many widespread depigmented macules over the entire body, with often a symmetrically distribution pattern.
•Stable means: no expansion of existing lesions or appearance of new lesions during the previous 6 months, absence of Koebner*s phenomenon and a positive minigrafting test
•ii. Patients, eligible for minigrafting and NB-UVB/excimer therapy
•iii. Adult patients: * 18 years
•iv. Patients who have given written informed consent

•i. With a history of hypertrophic scarring and/or keloid
•ii History of allergic/phototoxic reaction (Lidocaine, Tegaderm, Suture strips, sunlight)
•iii With a negative minigrafting test
•iv With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member)
•v. With a personal history of photosensitivity and/or phototoxicity disorders
•vi. With skin type I (according to Fitzpatrick classification I-VI)
•vii. Who are pregnant
•viii. Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s)
•ix. With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema.
•x. Who are not able to have 2 times weekly NB-UVB/Excimer therapy.
•xi. With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weekswill be required.

发起方